Sutro Biopharma宣布1比10的反向股票分割-动脉网

Sutro Biopharma Announces 1-for-10 Reverse Stock Split

Sutro Biopharma 等信源发布 2025-12-01 08:00



可切换为仅中文







SOUTH SAN FRANCISCO, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that its Board of Directors (Board) has approved a reverse stock split of the Company’s outstanding shares of common stock at a ratio of 1-for-10.

加利福尼亚州南旧金山，2025年12月1日（环球新闻社）——Sutro Biopharma, Inc.（Sutro或公司）（纳斯达克股票代码：STRO），一家处于临床阶段的肿瘤学公司，致力于开创位点特异性和新型抗体药物偶联物（ADCs），今天宣布其董事会已批准对公司流通在外的普通股进行1比10的反向股票分割。

The reverse stock split will become effective at 12:01 a.m. Eastern Time on December 3, 2025. Sutro’s common stock will begin trading on a post-reverse stock split basis on December 3, 2025, under the Company’s existing trading symbol “STRO” with a new CUSIP number of 869367201. The reverse stock split is intended to regain compliance with Nasdaq’s minimum bid price requirement of $1.00 per share..

反向股票分割将于2025年12月3日凌晨12:01（东部时间）生效。Sutro的普通股将于2025年12月3日开始在反向股票分割后的基础上进行交易，使用公司现有的交易代码“STRO”，新的CUSIP号码为869367201。此次反向股票分割旨在重新符合纳斯达克每股1.00美元的最低出价要求。

The reverse stock split was approved by Sutro’s stockholders at the Company’s 2025 annual meeting of stockholders held on June 6, 2025, to be effected at the Board’s discretion within approved parameters. The reverse stock split reduces the number of shares of the Company’s outstanding common stock from approximately 85,193,912 shares to approximately 8,519,392.

反向股票分割已在公司2025年6月6日举行的年度股东大会上获得Sutro股东的批准，将在董事会的酌情决定下于批准的参数内实施。反向股票分割将公司已发行普通股的股份数量从约85,193,912股减少至约8,519,392股。

As a result of the reverse stock split, proportionate adjustments will be made to the exercise prices and number of shares of Sutro’s common stock underlying the Company’s outstanding equity awards for common stock, as well as the number of shares issuable under the Company’s equity incentive and inducement plans, and employee stock purchase plan.

由于反向股票分割，公司将对现有股权奖励中与普通股相关的行使价格和股份数量进行相应调整，同时也会调整公司股权激励计划、诱导计划以及员工购股计划下的可发行股份数量。

There will be no change to the number of authorized shares or to the par value per share..

授权股份数量或每股面值均不会发生变化。

Information for Sutro’s Stockholders

Sutro股东信息

Sutro’s transfer agent, Equiniti Trust Company, LLC, will serve as the exchange agent for the reverse stock split. Registered stockholders holding pre-split shares of Sutro’s common stock electronically in book-entry form are not required to take any action to receive post-split shares. Those stockholders who hold their shares in brokerage accounts or in “street name” will have their positions automatically adjusted to reflect the reverse stock split, subject to each broker’s particular processes, and will not be required to take any action in connection with the reverse stock split.

Sutro的过户代理公司Equiniti Trust Company, LLC将担任此次反向股票分割的交换代理。持有Sutro普通股预分割股份的注册股东，若以电子形式记账持有，则无需采取任何行动即可收到分割后的股份。那些通过经纪账户或以“街名”持有股份的股东，其持仓将自动调整以反映反向股票分割，具体调整需遵循各经纪商的特定流程，且无需就反向股票分割采取任何行动。

None of Sutro’s common stock is held in certificate form. No fractional shares will be issued in connection with the reverse stock split. Stockholders who would otherwise be entitled to receive fractional shares will receive the number of shares of common stock as rounded up to the nearest whole share.

Sutro的普通股均不以证书形式持有。在反向股票分割过程中不会发行零碎股份。原本有权获得零碎股份的股东将收到向上取整至最接近的整数股份数量的普通股。

The reverse stock split will affect all of the Company’s stockholders uniformly and would not affect any stockholder’s percentage ownership interests, except to the extent that the reverse stock split results in such stockholder owning a fractional share..

反向股票分割将统一影响公司所有股东，且不会影响任何股东的百分比所有权，除非反向股票分割导致该股东持有零碎股份。

About Sutro Biopharma

关于Sutro Biopharma

Sutro Biopharma, Inc. is advancing a next-generation antibody-drug conjugate (ADC) platform designed to deliver single- and dual-payload ADCs that enable meaningful breakthroughs for patients with cancer. By fully optimizing the antibody, linker, and payload, Sutro’s cell-free platform produces ADCs that are engineered to improve drug exposure, reduce side effects, and expand the range of treatable tumor types.

Sutro Biopharma, Inc. 正在推进一种下一代抗体药物偶联物 (ADC) 平台，旨在提供单载荷和双载荷的 ADC，为癌症患者带来有意义的突破。通过全面优化抗体、连接子和载荷，Sutro 的无细胞平台生产的 ADC 旨在改善药物暴露、减少副作用，并扩大可治疗的肿瘤类型范围。

With unique capabilities in dual-payload ADCs, Sutro aims to overcome treatment resistance and redefine what’s possible in cancer therapy. The Company’s pipeline of single- and dual-payload ADCs targets large oncology markets with limited treatment options and significant need for improved therapies..

凭借在双载荷ADC领域的独特能力，Sutro旨在克服治疗耐药性，并重新定义癌症治疗的可能性。公司单载荷和双载荷ADC的研发管线针对治疗选择有限且对改进疗法需求巨大的大型肿瘤市场。

For more information, follow Sutro on social media @Sutrobio or visit

欲了解更多信息，请在社交媒体上关注 Sutro @Sutrobio 或访问

www.sutrobio.com

。

Forward Looking Statements

前瞻性声明

This press release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, including, but not limited to, Sutro’s future stock price, the effects of the reverse stock split on stockholders, compliance with Nasdaq listing standards and Sutro’s ability to remain listed on the Nasdaq Global Market.

本新闻稿包含1995年《私人证券诉讼改革法》“安全港”条款所指的前瞻性陈述，包括但不限于Sutro未来的股价、反向股票分割对股东的影响、对纳斯达克上市标准的合规性以及Sutro继续在纳斯达克全球市场上市的能力。

All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, the Company cannot guarantee future events, results, actions, levels of activity, performance or achievements, and the timing and results of biotechnology development and potential regulatory approval is inherently uncertain.

所有非历史事实的陈述都可能被视为前瞻性陈述。尽管公司认为这些前瞻性陈述中反映的预期是合理的，但公司无法保证未来事件、结果、行动、活动水平、表现或成就，且生物技术开发和潜在监管批准的时间与结果本质上存在不确定性。

Forward-looking statements are subject to risks and uncertainties that may cause the Company’s actual activities or results to differ significantly from those expressed in any forward-looking statement, including risks and uncertainties related to the Company’s ability to advance its product candidates, the receipt and timing of potential regulatory designations, approvals and commercialization of product candidates, the market size for the Company’s product candidates to be smaller than anticipated, clinical trial sites, supply chain and manufacturing facilities, the Company’s ability to obtain, maintain and recognize the benefits of certain designations received by product candidates, the timing and results of preclinical and clinical trials, the Company’s ability to fund development activities and achieve development goals, the Company’s ability to protect intellectual property, and the Company’s commercial collaborations with third partie.

前瞻性声明受到风险和不确定性的约束，可能导致公司的实际活动或结果与任何前瞻性声明中表达的内容显著不同，包括与公司推进其产品候选者能力相关的风险和不确定性、潜在监管认定的收据和时间、产品候选者的批准和商业化、公司产品候选者的市场规模小于预期、临床试验地点、供应链和制造设施、公司获得、维持并享有产品候选者所获特定认定之益处的能力、临床前和临床试验的时间与结果、公司为开发活动提供资金并实现开发目标的能力、公司保护知识产权的能力，以及公司与第三方的商业合作。

Investor Contact

投资者联系

Emily White

艾米丽·怀特

Sutro Biopharma

德罗生物制药

(650) 823-7681

ewhite@sutrobio.com

Media Contact

媒体联系人

Amy Bonanno

艾米·博纳诺